| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Executive Officer
1 company
Rachel McMinn is Chief Executive Officer at NGNE. Rachel McMinn's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $35.9M at current prices.
Net of sales, the NGNE filings show accumulation of 44,148 shares.
Rachel McMinn has 6 Form 4 filings on record from March 2024 to September 2026, all as Chief Executive Officer at Neurogene (NGNE), 2024–2026.
The 8 reported transactions were 3 option or other derivative awards, 2 stock awards, 1 option exercise and 1 open-market sale, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 1 purchase worth about $969K and 1 sale worth about $74K.
The only open-market purchase was 47,500 shares of NGNE at an average $20.40 on November 22, 2024, about $969K. Twelve months later NGNE was down 1%.
The only open-market sale was 3,352 shares of NGNE at an average $22.07 on March 26, 2026, about $74K.